We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, August 10th:
PulteGroup, Inc. (PHM - Free Report) : This homebuilder, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings advancing 4.5% over the last 60 days.
Triton International Limited : This rental and leasing services provider, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings rising 3.1% over the last 60 days.
UnitedHealth Group Incorporated (UNH - Free Report) : This diversified health care company, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.9% over the last 60 days.
UnitedHealth Group Incorporated Price and Consensus
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Top Ranked Growth Stocks to Buy for August 10th
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, August 10th:
PulteGroup, Inc. (PHM - Free Report) : This homebuilder, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings advancing 4.5% over the last 60 days.
PulteGroup, Inc. Price and Consensus
PulteGroup, Inc. price-consensus-chart | PulteGroup, Inc. Quote
PulteGroup's has a PEG ratio of 0.44, compared with 1.00 for the industry. The company possesses a Growth Score of A.
PulteGroup, Inc. PEG Ratio (TTM)
PulteGroup, Inc. peg-ratio-ttm | PulteGroup, Inc. Quote
Triton International Limited : This rental and leasing services provider, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings rising 3.1% over the last 60 days.
Triton International Limited Price and Consensus
Triton International Limited price-consensus-chart | Triton International Limited Quote
Triton has a PEG ratio 0.83, compared with 1.40 for the industry. The company possesses a Growth Score of A.
Triton International Limited PEG Ratio (TTM)
Triton International Limited peg-ratio-ttm | Triton International Limited Quote
UnitedHealth Group Incorporated (UNH - Free Report) : This diversified health care company, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.9% over the last 60 days.
UnitedHealth Group Incorporated Price and Consensus
UnitedHealth Group Incorporated price-consensus-chart | UnitedHealth Group Incorporated Quote
UnitedHealth has a PEG ratio of 1.54, compared with 1.93 for the industry. The company possesses a Growth Score of B.
UnitedHealth Group Incorporated PEG Ratio (TTM)
UnitedHealth Group Incorporated peg-ratio-ttm | UnitedHealth Group Incorporated Quote
See the full list of top ranked stocks here
Learn more about the Growth score and how it is calculated here.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>